1207360-89-1 Usage
Description
N-Ethyl-N'-[4-[5,6,7,8-tetrahydro-4-[(3S)-3-methyl-4-morpholinyl]-7-(3-oxetanyl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]urea is a complex organic compound characterized by its potent and selective inhibition of the mTOR pathway, which plays a crucial role in cell growth, proliferation, and survival. N-Ethyl-N'-[4-[5,6,7,8-tetrahydro-4-[(3S)-3-methyl-4-morpholinyl]-7-(3-oxetanyl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]urea has been found to exhibit dose-dependent efficacy in mouse xenograft cancer models, making it a promising candidate for further research and development in the field of oncology.
Uses
Used in Oncology:
N-Ethyl-N'-[4-[5,6,7,8-tetrahydro-4-[(3S)-3-methyl-4-morpholinyl]-7-(3-oxetanyl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]urea is used as a potent and selective mTOR inhibitor for the treatment of various types of cancer. Its application is based on its ability to inhibit the mTOR pathway, which is often dysregulated in cancer cells, leading to uncontrolled cell growth and proliferation. By targeting this pathway, the compound has the potential to slow down or halt tumor growth, offering a new therapeutic approach for cancer patients.
Used in Pharmaceutical Research:
In the pharmaceutical industry, N-Ethyl-N'-[4-[5,6,7,8-tetrahydro-4-[(3S)-3-methyl-4-morpholinyl]-7-(3-oxetanyl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]urea is used as a key compound in the development of new drugs targeting the mTOR pathway. Its potent and selective inhibition of mTOR makes it an attractive candidate for further optimization and modification to improve its pharmacological properties, such as bioavailability, stability, and specificity. This research could lead to the development of more effective and safer drugs for the treatment of cancer and other diseases associated with mTOR dysregulation.
Used in Drug Delivery Systems:
Similar to gallotannin, N-Ethyl-N'-[4-[5,6,7,8-tetrahydro-4-[(3S)-3-methyl-4-morpholinyl]-7-(3-oxetanyl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]urea may also benefit from the development of novel drug delivery systems to enhance its applications and efficacy against cancer cells. Various organic and metallic nanoparticles could be employed as carriers for this compound, aiming to improve its delivery, bioavailability, and therapeutic outcomes. This approach could potentially overcome limitations associated with the compound's pharmacokinetics and pharmacodynamics, leading to more effective cancer treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 1207360-89-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,0,7,3,6 and 0 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1207360-89:
(9*1)+(8*2)+(7*0)+(6*7)+(5*3)+(4*6)+(3*0)+(2*8)+(1*9)=131
131 % 10 = 1
So 1207360-89-1 is a valid CAS Registry Number.
1207360-89-1Relevant articles and documents
Discovery and biological profiling of potent and selective mTOR inhibitor GDC-0349
Pei, Zhonghua,Blackwood, Elizabeth,Liu, Lichuan,Malek, Shiva,Belvin, Marcia,Koehler, Michael F. T.,Ortwine, Daniel F.,Chen, Huifen,Cohen, Frederick,Kenny, Jane R.,Bergeron, Philippe,Lau, Kevin,Ly, Cuong,Zhao, Xianrui,Estrada, Anthony A.,Truong, Tom,Epler, Jennifer A.,Nonomiya, Jim,Trinh, Lan,Sideris, Steve,Lesnick, John,Bao, Linda,Vijapurkar, Ulka,Mukadam, Sophie,Tay, Suzanne,Deshmukh, Gauri,Chen, Yung-Hsiang,Ding, Xiao,Friedman, Lori S.,Lyssikatos, Joseph P.
supporting information, p. 103 - 107 (2013/02/26)
Aberrant activation of the PI3K-Akt-mTOR signaling pathway has been observed in human tumors and tumor cell lines, indicating that these protein kinases may be attractive therapeutic targets for treating cancer. Optimization of advanced lead 1 culminated in the discovery of clinical development candidate 8h, GDC-0349, a potent and selective ATP-competitive inhibitor of mTOR. GDC-0349 demonstrates pathway modulation and dose-dependent efficacy in mouse xenograft cancer models.
